TY - JOUR
T1 - Improved COVID-19 outcomes in a large non-invasive respiratory support cohort despite emergence of the alpha variant
AU - The Oxford Respiratory Group
AU - Turnbull, Chris D.
AU - Porter, Benedict M.L.
AU - Evans, Sarah B.
AU - Smith, Oliver
AU - Lardner, Rachel
AU - Hallifax, Robert
AU - Bettinson, Henry V.
AU - Talbot, Nicholas P.
AU - Bafadhel, Mona
AU - Rahman, Najib M.
AU - Petousi, Nayia
AU - Achaiah, Andrew
AU - Addala, Dinesh
AU - Banka, Radhika
AU - Bedawi, Eihab
AU - Chapman, Stephen
AU - Danbury, Hannah
AU - Couillard, Simon
AU - Douglas, Eric
AU - Elder, Patrick
AU - Fries, Anastasia
AU - Flight, William
AU - Fraser, Emily
AU - Hardinge, Maxine
AU - Hinks, Timothy
AU - Ho, Ling Pei
AU - Hoyles, Rachel
AU - Melhorn, James
AU - Moore, Alastair
AU - Nathwani, Vishal
AU - Nickol, Annabel
AU - Park, John
AU - Patel, Shefaly
AU - Pavord, Ian
AU - Rothwell, Evie
AU - Saunders, Peter
AU - Laurenson-Schafer, Hannah
AU - Roxburgh, Francesca
AU - Sundaralingam, Anand
AU - Sykes, Anny
AU - Tsakok, Maria
AU - Wilson, Robert
AU - Wrightson, John M.
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2021.
PY - 2021/11/30
Y1 - 2021/11/30
N2 - Introduction Respiratory high-dependency units (rHDUs) are used to manage respiratory failure in COVID-19 outside of the intensive care unit (ICU). The alpha variant of COVID-19 has been linked to increased rates of mortality and admission to ICU; however, its impact on a rHDU population is not known. We aimed to compare rHDU outcomes between the two main UK waves of COVID-19 infection and evaluate the impact of the alpha variant on second wave outcomes. Methods We conducted a single-centre, retrospective analysis of all patients with a diagnosis of COVID-19 admitted to the rHDU of our teaching hospital for respiratory support during the first and second main UK waves. Results In total, 348 patients were admitted to rHDU. In the second wave, mortality (26.7% s vs 50.7% first wave, χ2=14.7, df=1, p=0.0001) and intubation rates in those eligible (24.3% s vs 58.8% first wave, χ2=17.3, df=2, p=0.0002) were improved compared with the first wave. In the second wave, the alpha variant had no effect on mortality (OR 1.18, 95% CI 0.60 to 2.32, p=0.64). Continuous positive airway pressure (CPAP) (89.5%) and awake proning (85.6%) were used in most patients in the second wave. Discussion Our single-centre experience shows that rHDU mortality and intubation rates have improved over time in spite of the emergence of the alpha variant. Our data support the use of CPAP and awake proning, although improvements in outcome are likely to be multifactorial.
AB - Introduction Respiratory high-dependency units (rHDUs) are used to manage respiratory failure in COVID-19 outside of the intensive care unit (ICU). The alpha variant of COVID-19 has been linked to increased rates of mortality and admission to ICU; however, its impact on a rHDU population is not known. We aimed to compare rHDU outcomes between the two main UK waves of COVID-19 infection and evaluate the impact of the alpha variant on second wave outcomes. Methods We conducted a single-centre, retrospective analysis of all patients with a diagnosis of COVID-19 admitted to the rHDU of our teaching hospital for respiratory support during the first and second main UK waves. Results In total, 348 patients were admitted to rHDU. In the second wave, mortality (26.7% s vs 50.7% first wave, χ2=14.7, df=1, p=0.0001) and intubation rates in those eligible (24.3% s vs 58.8% first wave, χ2=17.3, df=2, p=0.0002) were improved compared with the first wave. In the second wave, the alpha variant had no effect on mortality (OR 1.18, 95% CI 0.60 to 2.32, p=0.64). Continuous positive airway pressure (CPAP) (89.5%) and awake proning (85.6%) were used in most patients in the second wave. Discussion Our single-centre experience shows that rHDU mortality and intubation rates have improved over time in spite of the emergence of the alpha variant. Our data support the use of CPAP and awake proning, although improvements in outcome are likely to be multifactorial.
U2 - 10.1136/bmjresp-2021-001044
DO - 10.1136/bmjresp-2021-001044
M3 - Article
C2 - 34848495
AN - SCOPUS:85122442637
SN - 2052-4439
VL - 8
JO - BMJ Open Respiratory Research
JF - BMJ Open Respiratory Research
IS - 1
M1 - e001044
ER -